Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 27, 2014. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share capital movements.
- Shares Purchased: 119,000 Ordinary Shares of 25 pence each.
- Purchase Date: February 27, 2014.
- Price Range: Highest price paid was 1,698.00 pence per share; lowest price paid was 1,679.50 pence per share.
- Treasury Holdings (Settled): 488,815,169 shares (9.14% of total issued share capital).
- Treasury Holdings (Including Unsettled): 489,174,669 shares (10.07% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,858,684,836 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 119,000 shares for treasury. Consequently, the percentage of total voting rights held in treasury increased to 10.07% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (4,858,684,836) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current treasury share percentage (10.07% of voting rights) to assess potential dilution or buyback capacity.
- Note that this announcement does not constitute an offer to purchase or subscribe for securities.